NIH R01 · 2025
PROJECT SUMMARY Type 1 diabetes (T1D) results from the destruction of insulin producing β-cells upon immune infiltration and inflammation of the islets of Langerhans in the pancreas. Prior to T1D onset there is an asymptomatic phase of many years which presents a window for therapeutic intervention. However, there are limited means for detecting and tracking the development of insulitis in this ‘pre-symptomatic’ T1D window, to guide and monitor therapeutic interventions. Ultrasound imaging presents many advantages for clinical deployment, and gas- filled microbubble (MB) contrast agents are clinically approved, and used in detection and monitoring of a wide range of diseases. We previously…
From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.